Recursion Pharmaceuticals (RXRX) Enterprise Value (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted Enterprise Value of -$660.0 million for Q1 2026, up 11.75% on a QoQ basis from -$747.9 million in Q4 2025, and down 31.07% year-over-year from -$957.5 million in Q1 2025.
Recursion Pharmaceuticals (RXRX) Enterprise Value (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Enterprise Value history runs 7 years deep, the most recent figure standing at -$660.0 million for Q1 2026.
- Quarterly Enterprise Value fell 31.07% year-over-year to -$660.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$660.0 million (down 31.07% YoY) and the FY2025 annual result came in at -$747.9 million, down 25.19% from the prior year.
- Enterprise Value was -$660.0 million for Q1 2026 at Recursion Pharmaceuticals, up from -$747.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$299.5 million in Q1 2024 and bottomed at -$747.9 million in Q4 2025.
- A 5-year average of -$502.7 million and a median of -$476.1 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value tumbled 132.47% — and 2024, when it surged 36.87%.
- Recursion Pharmaceuticals' Enterprise Value stood at -$551.2 million in 2022, then advanced by 28.37% to -$394.8 million in 2023, then plunged by 51.32% to -$597.4 million in 2024, then fell by 25.19% to -$747.9 million in 2025, then gained by 11.75% to -$660.0 million in 2026.
- Business Quant data shows RXRX's Enterprise Value at -$660.0 million in Q1 2026, -$747.9 million in Q4 2025, and -$663.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | -659.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -659.98 Mn |
| Dec 31, 2025 | -747.89 Mn |
| Sep 30, 2025 | -662.97 Mn |
| Jun 30, 2025 | -528.22 Mn |
| Mar 31, 2025 | -503.53 Mn |
| Dec 31, 2024 | -597.40 Mn |
| Sep 30, 2024 | -429.20 Mn |
| Jun 30, 2024 | -476.12 Mn |
| Mar 31, 2024 | -299.52 Mn |
| Dec 31, 2023 | -394.80 Mn |
| Sep 30, 2023 | -389.58 Mn |
| Jun 30, 2023 | -409.20 Mn |
| Mar 31, 2023 | -474.46 Mn |
| Dec 31, 2022 | -551.19 Mn |
| Sep 30, 2022 | -456.74 Mn |
| Jun 30, 2022 | -455.78 Mn |
| Mar 31, 2022 | -509.41 Mn |
| Dec 31, 2021 | -516.56 Mn |
| Sep 30, 2021 | -578.91 Mn |
| Jun 30, 2021 | -642.97 Mn |